PCOS Is Now PMOS: Why This Name Change Is Bigger Than You Think

A landmark global consensus has renamed a condition affecting 170 million women. Here is what it means, and why it took this long.

For decades, millions of women have lived with a condition that medicine struggled to name accurately, diagnose consistently, or treat holistically. That has now changed, at least on paper. In February 2026, patients and health professionals reached agreement on a new name: polyendocrine metabolic ovarian syndrome, or PMOS. The consensus was formally published in The Lancet on May 12, 2026. The LancetContemporary OB/GYN

It replaces the four-decade-old label polycystic ovary syndrome, or PCOS. And while a name change might seem like administrative housekeeping, this one carries real weight.

Why the Old Name Was the Problem

For too long, the name reduced a complex, long-term hormonal and endocrine disorder to a misunderstanding about cysts and a narrow focus on the ovaries. This contributed to missed diagnoses and inadequate treatment. Endocrine Society

The cyst framing was not just inaccurate. It was actively harmful. When women were told they had a “cyst condition,” many sought cyst-related answers, were referred to gynaecologists alone, and had their broader hormonal and metabolic symptoms overlooked or attributed to stress, weight, or lifestyle. The condition remains underdiagnosed in up to 70% of affected patients. Conexiant

Although the condition requires long-term management, many women encountered fragmented information, inconsistent explanations, and delayed diagnoses during clinical encounters. These unmet informational and emotional needs increased psychological distress, reduced treatment adherence, and impeded lifestyle modification, cumulatively worsening health-related quality of life. nih

This was a systemic failure dressed up as a naming convention.

What the New Name Actually Captures

The word “polyendocrine” recognises that the condition is underpinned by multiple interacting hormonal disturbances, including insulin, androgens, and neuroendocrine hormones, rather than being an isolated ovarian disorder. “Metabolic” acknowledges the inherent metabolic features such as insulin resistance. Contemporary OB/GYN

The new name recognises that the condition is not a primarily gynaecological disorder, but is instead a complex, multisystem condition involving endocrine, metabolic, reproductive, dermatological, and psychological health. CU Anschutz Medical Campus

In plain terms: this is a condition that touches hormones, metabolism, fertility, cardiovascular health, mental wellbeing, skin, and weight regulation. It is a full-body condition. The new name finally says so.

A Process Built on Real Voices

This was not a decision made in a room full of specialists. After hearing from 22,000 people over 11 years, the renaming process drew on clinicians, researchers, patients, and charities from around the globe. Statnews

The international initiative engaged 56 academic, clinical, and patient organisations across multiple world regions and used Delphi surveys and consensus workshops to evaluate potential terminology. Surveys conducted in 2025 and 2026 included more than 14,000 patients and health professionals. Among the guiding principles for the new terminology were scientific accuracy, clarity, avoidance of stigma, cultural appropriateness, and implementation feasibility. Conexiant

The process was led by Professor Helena Teede, Director of the Monash Centre for Health Research and Implementation and an endocrinologist at Monash Health, who spent decades researching the condition and witnessing its patient impacts firsthand. EurekAlert!

That it took a woman researcher at Monash, working in partnership with patients, to drive this change is not incidental. It is the story of women’s health in miniature.

The Cost of Getting the Name Wrong

Behind the clinical language is a very human toll. Women with PCOS have described years of being sent from one specialist to another, of having weight blamed for their symptoms rather than symptoms being seen as the cause of weight challenges, of fertility struggles framed as personal failures rather than hormonal realities, of depression and anxiety dismissed as secondary concerns.

The condition has historically been associated with diagnostic delays, fragmented multidisciplinary care, and significant psychosocial stigma. Cardiometabolic risk is among the most clinically underappreciated dimensions of the condition. Patient Care Online

This matters because cardiovascular disease is not a distant risk. For women with PMOS, elevated androgen levels and insulin resistance create a compounding burden that plays out over decades. When the name pointed only at ovaries, the heart was invisible.

What Changes Now, and What Still Needs To

The new name is expected to usher in a new era of awareness, research, and improved outcomes for millions of patients around the world. As one researcher involved in the process noted, it sets the foundation for meaningful change, from medical education to clinical guidelines to public awareness. CU Anschutz Medical Campus

Practically, the transition will take time. A transition roadmap developed in 2025 and 2026 is designed to support adoption across clinical practice, research, education, and public communication. Diagnostic coding systems, medical curricula, patient literature, and prescription labels will all need updating. The Lancet

A better name will not solve every problem, but it can make the first conversation more honest. ESSI

That first conversation matters enormously. It is the one where a woman sits in a clinic and is either seen fully or reduced to one symptom. It is the one that either opens a door to integrated care or sends her home with a pamphlet about cysts and a follow-up in six months.

Why SheSight Is Watching This Closely

At SheSight, we have covered women’s health at the intersection of science, lived experience, and systemic change. The PMOS renaming sits squarely at that intersection.

The condition affects 1 in 8 women. That means it is in our workplaces, our families, our networks, and our communities in ways we may not even know yet. Many women currently living with irregular cycles, unexplained fatigue, insulin resistance, fertility challenges, or mood disruptions have never been assessed for what was previously called PCOS and is now PMOS, often because no one ever connected those dots for them.

A name change is a beginning, not an ending. But this one redraws the map. It signals that women’s health deserves the same precision, the same systemic thinking, and the same urgency that medicine applies when it is paying attention.

It has been a long time coming.

Sources: The Lancet, May 2026; The Endocrine Society; Monash University; STAT News; EurekAlert